## Highlights of This Issue 5839

### SPECIAL FEATURES

#### CCR Translations

5841  Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma  
Michael R. Harrison and Daniel J. George  
See article p. 6021

#### Molecular Pathways

5844  Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone  
James L. Mohler, Mark A. Titus, and Elizabeth M. Wilson

5850  ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease  
Maria Soledad Sosa, Alvaro Avivar-Valderas, Paloma Bragado, Huet-Chi Wen, and Julio A. Aguirre-Ghiso

#### Review

5858  Thrombotic Microangiopathy with Targeted Cancer Agents  
John A. Blake-Haskins, Robert J. Lechleider, and Robert J. Kreitman

#### HUMAN CANCER BIOLOGY

5867  Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System  
Andrew V. Kossenkov, Anil Vachani, Celia Chang, Calen Nichols, Shere Billouin, Wenhwai Horng, William N. Rom, Steven M. Albeda, Michael K. Showe, and Louise C. Showe

5878  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy  
Sarah Minner, Malaiak Enodien, Huseyn Sirma, Andreas M. Luebke, Antje Krohn, Pascale S. Mayer, Ronald Simon, Pierre Tennstedt, Julia Muller, Laura Scholz, Jan C. Brase, Alvin Y. Liu, Hartmut Schluter, Klaus Pantel, Udo Schumacher, Carsten Bokemeyer, Thomas Steuber, Markus Graefen, Guido Sauter, and Thorsten Schlemm

5889  Characterization of a Cleavage Stimulation Factor, 3′ pre-RNA, Subunit 2, 64 kDa (CSTF2) as a Therapeutic Target for Lung Cancer  
Masato Aragaki, Koji Takahashi, Hirohiko Akiyama, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, and Yataro Daigo

## CANCER THERAPY: PRECLINICAL

5901  Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma  
Xianbiao Xie, Markus P.H. Ghadimi, Eric D. Young, Roman Belousov, Quan-sheng Zhu, Juehui Liu, Gonzalo Lopez, Chiara Colombo, Tingsheng Peng, David Reynoso, Jason L. Hornick, Alexander J. Lazar, and Dina Lev

5913  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants  

5926  Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody  
Xing Du, Laiman Xiang, Crystal Mackall, and Ira Pastan

5935  Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance  
Kelly M. Quesnelle and Jennifer R. Grandis
Targeting Human B-cell Malignancies through Ig Light Chain–Specific Cytotoxic T Lymphocytes
Jinseng Weng, Soung-Chul Cha, Satoko Matsueda, Gheath Alatrash, Michael S. Popescu, Qing Yi, Jeffrey J. Moldtrem, Michael Wang, Sattra S. Neelapu, and Larry W. Kwak

Curcumin Treatment Suppresses IKKβ Kinase Activity of Salivary Cells of Patients with Head and Neck Cancer: A Pilot Study
Suejung G. Kim, Mysore S. Veena, Saroj K. Basak, Eugene Han, Tracey Tajima, David W. Gjertson, Joshua Starr, Ofer Eidelman, Harvey B. Pollard, Meera Srivastava, Eri S. Srivatsan, and Marlene B. Wang

Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor
Niels Jørgen Østergaard Skartved, Helle Jane Jacobsen, Mikkel Wandahl Pedersen, Pernille Foged Jensen, Jette Wagtberg Sen, Thomas Kjærgaard Jørgensen, Adam Hey, and Michael Kragh

ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bel-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents
Cyrille Touzeau, Christelle Dousset, Linda Bodet, Patricia Gomez-Bougie, Stéphanie Bonnand, Anne Moreau, Philippe Moreau, Catherine Pollat-Decenyynk, Martine Amiot, and Steven Le Gouill

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
Irfan Kayani, Norbert Avril, Jamshed Romanji, Simon Chowdhury, Andrea Rockall, Anju Sahdev, Paul Nathan, Peter Wilson, Jonathan Shamash, Kevin Sharpe, Louise Lim, John Dickson, Peter Ell, Andrew Reynolds, and Thomas Powles

See commentary p. 5841

Prognostic Impact of ΔTAp73 Isoform Levels and Their Target Genes in Colon Cancer Patients
Beatriz Soldevilla, Raquel Díaz, Javier Silva, Yolanda Campos-Martín, Concepción Muñoz, Vanesa García, José M García, Cristina Peña, Mercedes Herrera, Marta Rodríguez, Irene Gómez, Nagat Mohamed, Margarita M. Marques, Félix Bonilla, and Gemma Domínguez

Upregulation of Rac GTPase-Activating Protein 1 Is Significantly Associated with the Early Recurrence of Human Hepatocellular Carcinoma
Suk Mei Wang, London Lucien P.J. Ooi, and Kam M. Hui

Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
Aung Naing, Razelle Kurzrock, Angelika Burger, Sachin Gupta, Xiudong Lei, Naifa Busaidy, David Hong, Helen X. Chen, Lawrence A. Doyle, Lance K. Heilbrun, Eric Rohren, Chaan Ng, Chandtip Chandhasin, and Patricia LoRusso
Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response

ABOUT THE COVER
Interleukin-6 (IL-6) has tumor-promoting actions on both malignant and stromal cells in a range of experimental cancer models. In addition, high plasma IL-6 levels are associated with poor prognosis in ovarian cancer, but there is little information as to the source of this IL-6. Ovarian cancer biopsies were stained for IL-6 (left) and automated algorithms used to assess both malignant (right) and stromal (middle) compartments. Expression levels were quantified using an autoscore that combined both the intensity and density of positive pixels. IL-6 staining was seen in both the malignant and nonmalignant cells, but was significantly higher in the malignant cell areas. For further details, see Coward and colleagues on page 6083 of this issue.
Clinical Cancer Research

17 (18)

Clin Cancer Res 2011;17:5839-6105.

Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/17/18

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.